spacer
home > ict > spring 2020 > comparator sourcing in clinical studies (part two of two)
PUBLICATIONS
International Clinical Trials

Comparator Sourcing in Clinical Studies (Part Two of Two)



Due to the free movement of trade, European medicinal wholesalers are not obliged to exclusively supply domestic markets and can also export products to foreign clients or sell to sponsors conducting clinical trials. The market is highly volatile with prices and availability of drug product changing frequently. Understanding the rules of trade and commerce is, therefore, a key requisite when dealing with comparator suppliers and their wholesalers in this sector. Although sponsors like to plan drug requirements often over a year in advance, wholesale stock options seldom remain available for longer than a few weeks. Sponsors rarely understand this, assuming that all stock options are being quoted from innovator channels where endless reserves of product are stored in huge warehouses. Avoiding wastage through accurate supply and demand forecasting has now become a critical issue for pharma companies in both clinical trial and commercial settings. This means we are seeing more ‘just-intime’ manufacturing and less stockpiles of comparator drugs available in the wholesale sector. A comparator vendor must have a baseline understanding of pricing and ongoing drug availability in each market and be able to negotiate the right price for the product on the sponsor’s behalf. One essential factor when selecting a comparator supplier is that they have a wide selection of wholesale suppliers – each of whom can supply the same comparator product. In this way, if one or several wholesalers fail to supply, there is always a back-up option in place.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author

Toby Watkins is the Founder and Managing Director of a Swiss-based clinical trial supplies consultancy firm, CTSS, that helps sponsors identify, validate, and manage vendor companies across the CTS value chain. Over the last decade, Toby has worked on global comparator sourcing programmes helping sponsors source comparator drugs, ancillaries, and reference products and identify their vendors in over 30 countries around the globe. Prior to entering the clinical arena, he worked on named-patient and managed access programmes in emerging markets. Toby has had the privilege of working with many of the world’s innovators, comparator sourcing companies, CROs, CMOs, biotechs, Big Pharma companies, and their suppliers at every stage of drug development across multiple indications.

toby.watkins@clinicaltrialsupplysolutions.com
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cellefill™, a New Integrated Solution to Fast-Track Cell, Gene and Biological Therapies

24 August 2022, Falmouth, UK: Aseptic fill/finish experts Flexicon Liquid Filling, part of Watson-Marlow Fluid Technology Solutions (WMFTS), and barrier technology specialists Franz Ziel GmbH, today announce the launch of Cellefill™- a turnkey, vial fill/finish system with an integrated barrier solution.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: Summary of Year 2013

Synergy Research Group

Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement